老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
iShares Health Innovation Active ETF
33.56
0.0000
成交量：
69
成交額：
2,349.44
市值：
1,342.44萬
市盈率：
- -
高：
33.56
開：
33.56
低：
33.56
收：
33.56
52周最高：
34.86
52周最低：
25.79
股本：
40.00萬
流通股本：
40.00萬
量比：
0.13
換手率：
0.02%
股息：
0.08
股息率：
0.24%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
特朗普政府宣佈撥款1.493億美元，用於在阿肯色州農村地區擴展遠程醫療，並增加專科護理和預防性篩查的可及性。
智通财经
·
09/01
衞材宣佈：加拿大藥品管理局最終推薦侖卡奈單抗（Leqembi）在早期阿爾茨海默病中獲得報銷資格
美股速递
·
09/01
長春高新(000661.SZ)子公司GenSci161注射液臨床試驗申請獲受理
智通财经
·
08/31
石藥集團(01093.HK)：SYH2092注射液用於成人超重或肥胖患者體重管理的I期臨床試驗在中國首個研究中心正式啓動
智通财经
·
08/31
石藥集團(01093)：SYH2092注射液用於成人超重或肥胖患者體重管理的I期臨床試驗在中國首個研究中心正式啓動
智通财经
·
08/31
長春高新：子公司GenSci161注射液境內生產藥品註冊臨床試驗申請獲受理
智通财经
·
08/31
石藥創新：控股子公司SYH2092注射液啓動Ⅰ期臨床試驗
智通财经
·
08/31
歐康維視生物-B(01477)：OT-202 III期臨床試驗完成首例患者入組
智通财经
·
08/31
ST百靈(002424.SZ)子公司創新藥吸入用BD77臨床試驗申請獲批
智通财经
·
08/31
ST百靈：全資子公司吸入用BD77獲臨床試驗批准
智通财经
·
08/31
樂意保®（侖卡奈單抗）皮下自動注射劑型LEQEMBI IQLIK®在美上市，適用於早期阿爾茨海默病的初始治療
美通社
·
08/31
港股異動 | 和譽-B(02256)高開逾6% ABSK211的I期臨床試驗完成首例患者給藥
智通财经
·
08/31
和譽-B(02256)：新型pan-KRAS抑制劑ABSK211I期臨床試驗完成首例患者給藥
智通财经
·
08/31
和譽-B(02256.HK)：新型pan-KRAS抑制劑ABSK211I期臨床試驗完成首例患者給藥
智通财经
·
08/31
BioNTech在進行安全性審查後終止了mRNA結直腸癌疫苗的臨床試驗
路透中文
·
08/28
美股生物醫藥股盤初走低，BioNTech跌超9%、Moderna跌近5%
老虎资讯综合
·
08/28
BioNTech美股盤前跌約10%，公司宣佈終止二期結直腸癌臨床試驗。
智通财经
·
08/28
BIONTECH結束二期結直腸癌臨床試驗。
智通财经
·
08/28
台裕製藥提交針對HER2陽性乳腺癌的抗體藥物偶聯物生物類似藥TSY-110的臨床試驗申請。
智通财经
·
08/28
焦點-歷經一個世紀的失敗後終於取得成功：揭秘莫德納和默克癌症疫苗的突破
路透中文
·
08/28
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BMED/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.5609,"timestamp":1789657525735,"preClose":33.5609,"halted":0,"volume":69,"delay":0,"changeRate":0,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-17 15:21:09 EDT","open":33.5609,"high":33.5609,"low":33.5609,"amount":2349.444687,"amplitude":0,"askPrice":34.16,"askSize":1000,"bidPrice":34.08,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":33.5609,"sharesOutstanding":360000,"nav":33.339378,"aum":13335751.2,"dividendRate":0.002375,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.41,"preClose":33.5609,"latestTime":"16:10 EDT","volume":6,"amount":201.3654,"timestamp":1789589403907,"change":-0.1509,"changeRate":-0.004496,"amplitude":0},"volumeRatio":0.132586,"impliedVol":0.0628,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.132586,"shares":400000,"dividePrice":0.0797,"high":33.5609,"amplitude":0,"preClose":33.5609,"low":33.5609,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.5609,"eps":0,"divideRate":0.002375,"volume":69,"delay":0,"ttmEps":0,"open":33.5609,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":32.8027,"twentyDayClose":34.7939,"sixtyDayClose":28.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664811000","title":"特朗普政府宣佈撥款1.493億美元，用於在阿肯色州農村地區擴展遠程醫療，並增加專科護理和預防性篩查的可及性。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811000?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 02:17","pubTimestamp":1788200232,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IEIH","HTEC","GDOC","FDHT","HEAL","LGHT","EKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110244724","title":"衞材宣佈：加拿大藥品管理局最終推薦侖卡奈單抗（Leqembi）在早期阿爾茨海默病中獲得報銷資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1110244724","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110244724?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 02:08","pubTimestamp":1788199690,"startTime":"0","endTime":"0","summary":"卫材今日宣布，加拿大药品管理局已就仑卡奈单抗在早期阿尔茨海默病治疗中的报销事宜发布最终积极推荐。这一决定意味着，符合条件的加拿大患者将有望获得这一创新疗法的公共资金支持。加拿大药品管理局经过严谨的临床证据评估后，最终给出了肯定意见。卫材公司表示，将继续与加拿大各省及地区的卫生部门密切协作，推动报销政策的实际落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BMED","BK4532","BIIB","IE00B894F039.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0109394709.USD","LU0234570918.USD","BK4139","LU0320765992.SGD","BK4533","BK4588","LU0889565916.HKD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003390","title":"長春高新(000661.SZ)子公司GenSci161注射液臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003390","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003390?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 20:25","pubTimestamp":1788179110,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GenSci161注射液的境内生产药品注册临床试验申请获得受理。GenSci161注射液是金赛药业自主研发的一款治疗用生物制品1类药物，拟用于治疗结缔组织病相关间质性肺疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","PSYK","BK0057","MDTX","BK0075","BK0046","IBBQ","BK0239","BMED","BK0028","BK0188","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663359008","title":"石藥集團(01093.HK)：SYH2092注射液用於成人超重或肥胖患者體重管理的I期臨床試驗在中國首個研究中心正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2663359008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663359008?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:58","pubTimestamp":1788177490,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BMED","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008368","title":"石藥集團(01093)：SYH2092注射液用於成人超重或肥胖患者體重管理的I期臨床試驗在中國首個研究中心正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008368","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008368?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:58","pubTimestamp":1788177490,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2092注射液用于成人超重或肥胖患者体重管理的I期临床试验已在中国首个研究中心正式启动。集团已于2026年8月获得中国国家药品监督管理局就该产品签发的药物临床试验批准通知书，并于获批后启动该产品的I期临床试验。本次启动的I期临床试验旨在评价该产品在健康参与者中单次给药的安全性、耐受性、药代动力学和药效学的临床试验。该I期临床试验的参与者招募和筛选工作正在积极推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","LU0067412154.USD","BMED","BK1191","LU0314109678.HKD","LU1226287875.USD","LU0326950275.SGD","LU1951186391.HKD","PSYK","IE00BZ08YR35.GBP","LU1226287792.SGD","IE00BZ08YT58.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","IE0008368742.USD","LU1328277881.USD","IBBJ","LU1008478684.HKD","LU1226288253.USD","LU1960683339.HKD","BK1521","IBBQ","IE00B031HY20.USD","LU1807302812.USD","LU1813983027.USD","IE00B543WZ88.USD","LU1152091168.USD","IE0008369823.USD","LU0880133367.SGD","LU1993786604.SGD","MDTX","BK1515","LU1226287529.USD","01093","SG9999004220.SGD","HK0000165453.HKD","LU2039709279.SGD","LU0315179316.USD","LU0501845795.SGD","LU0140636845.USD","KURE","LU0072913022.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663070352","title":"長春高新：子公司GenSci161注射液境內生產藥品註冊臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2663070352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663070352?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:29","pubTimestamp":1788175748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBQ","PSYK","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077697","title":"石藥創新：控股子公司SYH2092注射液啓動Ⅰ期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077697","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077697?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:08","pubTimestamp":1788174515,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","MDTX","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074148","title":"歐康維視生物-B(01477)：OT-202 III期臨床試驗完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074148","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074148?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:26","pubTimestamp":1788171975,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，用于治疗干眼症的 OT-202于中国进行的III期临床试验已完成首例患者入组。首例患者成功入组标志着OT-202在中国临床开发的一项重要里程碑，并体现集团为干眼症患者推进创新疗法的承诺。OT-202的II期临床试验，已于2023年11月于中国完成合共213名患者的II期临床试验入组。OT-202的II期临床试验结果已在国际顶尖眼科期刊《Ophthalmology》发表。2024年3月，OT-202的II期临床试验达到其主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","BK1191","BMED","BK1574","MDTX","01477","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079555","title":"ST百靈(002424.SZ)子公司創新藥吸入用BD77臨床試驗申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079555?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 17:29","pubTimestamp":1788168556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST百灵 发布公告，近日，公司全资子公司百灵毓秀(珠海)医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司创新药吸入用BD77临床试验申请获得批准，同意开展用于慢性阻塞性肺病的临床试验。据悉，吸入用BD77是来源于单一法定中药材经分离纯化获得的纯度超过98%的小分子化学药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LNGR","MEDX","BK0146","159992","BK0183","PSYK","IBBJ","MDTX","BMED","06978","IBBQ","BK1574","BK1161","BK0188","BK0077","002424","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663107696","title":"ST百靈：全資子公司吸入用BD77獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2663107696","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663107696?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 17:11","pubTimestamp":1788167518,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","IBBJ","BMED","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663734390","title":"樂意保®（侖卡奈單抗）皮下自動注射劑型LEQEMBI IQLIK®在美上市，適用於早期阿爾茨海默病的初始治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2663734390","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663734390?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 14:47","pubTimestamp":1788158820,"startTime":"0","endTime":"0","summary":"乐意保皮下自动注射剂型已获美国FDA批准，是全球首个可为初始治疗和维持治疗提供居家给药选择的抗淀粉样蛋白疗法。贯穿阿尔茨海默病治疗全程，提升治疗便利性与灵活性 在美国，乐意保皮下自动注射剂型已可用于初始治疗及维持治疗。该剂型有望进一步提升治疗的便利性和灵活性，使早期阿尔茨海默病患者及其照护伙伴在疾病管理中获得更大的自主权，同时可能降低患者启动和持续使用乐意保治疗的阻碍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5036748_ZH36748_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5036748_ZH36748_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B894F039.SGD","PBE","LU0234570918.USD","BK4533","BMED","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","BK4588","LU0109394709.USD","BK4585","BK4532","IE00B19Z9P08.USD","BIIB","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663256870","title":"港股異動 | 和譽-B(02256)高開逾6% ABSK211的I期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2663256870","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663256870?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 09:26","pubTimestamp":1788139577,"startTime":"0","endTime":"0","summary":"消息面上，8月31日，和誉-B发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布其口服、高效力且广泛覆盖多种KRAS改变的小分子pan-KRAS抑制剂ABSK211用于治疗携带KRAS基因改变的晚期实体瘤患者的I期临床试验已完成首例患者给药。临床前研究结果显示，ABSK211在单药及联合治疗场景中均展现出积极的抗肿瘤活性及良好的选择性，有望为携带KRAS基因改变的实体瘤患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","LU2476274720.SGD","BK4585","MDTX","VXUS","LU2778985437.USD","IE00B5MMRT66.SGD","BMED","BK1161","BK4588","KCAI","IE00B543WZ88.USD","02256","LU2488822045.USD","IBBQ","LU2476274308.USD","IBBJ","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663724028","title":"和譽-B(02256)：新型pan-KRAS抑制劑ABSK211I期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2663724028","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663724028?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 08:20","pubTimestamp":1788135636,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(“和誉医药”)宣布其口服、高效力且广泛覆盖多种KRAS改变的小分子pan-KRAS抑制剂ABSK211用于治疗携带KRAS基因改变的晚期实体瘤患者的I期临床试验已完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","LU2778985437.USD","IE00B5MMRT66.SGD","IBBJ","IE00B543WZ88.USD","IE00BPRC5H50.USD","IBBQ","BMED","PSYK","02256","BK1161","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663717028","title":"和譽-B(02256.HK)：新型pan-KRAS抑制劑ABSK211I期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2663717028","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663717028?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 08:20","pubTimestamp":1788135636,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","BMED","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662096800","title":"BioNTech在進行安全性審查後終止了mRNA結直腸癌疫苗的臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2662096800","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662096800?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 21:40","pubTimestamp":1787924401,"startTime":"0","endTime":"0","summary":"BioNTech此次临床试验失败，正值默克公司MRK.N和莫德纳公司MRNA.O宣布其基于mRNA的疫苗 在一项 涉及1,000多名患者的试验中，成功帮助预防了黑色素瘤复发和扩散的数日之后。负责监督BioNTech试验安全性和完整性的委员会发现，研究中各患者组在总生存期方面存在“数值不平衡”。BioNTech未对置评请求作出回应。BioNTech 还在开发其他基于 mRNA 的癌症疗法，包括用于头颈部癌症的 BNT113。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4S44P140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","LU0985320562.USD","IDNA","RXL","LU0265550359.USD","IXJ","LU0238689110.USD","LU0942090050.USD","BK4550","IE00B1BXHZ80.USD","IE00BLSP4239.USD","IE00BSNM7G36.USD","LU2491049909.HKD","LU1116320901.HKD","PPH","FHLC","VHT","JDOC","LU1699723380.USD","XLV","IE0002141913.USD","LU1116320737.USD","MRNY","LU0648001328.SGD","LU0868494708.USD","LGHT","LU1989772840.SGD","LU0130102774.USD","GNOM","BMED","PAWZ","LU2112291526.USD","SG9999014575.USD","BNTX","SGXZ57979304.SGD","IE00BBT3K403.USD","FTXH","GDOC","MRNX","LU0070302665.USD","TRUH","HRTS","IHE","SG9999015358.SGD","MRNA","SG9999015341.SGD","IE00B2B36J28.USD","MRK","WDNA","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100460280","title":"美股生物醫藥股盤初走低，BioNTech跌超9%、Moderna跌近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100460280","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100460280?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 21:37","pubTimestamp":1787924271,"startTime":"0","endTime":"0","summary":"8月28日，美股生物医药股盘初走低，$BioNTech(BNTX)$跌超9%，公司宣布终止结直肠癌2期临床试验；$Moderna(MRNA)$跌近5%，$默沙东(MRK)$跌1.5%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","IXJ","LU1941712348.USD","LU1069347547.HKD","SG9999014542.SGD","IE00BFTCPJ56.SGD","IBBJ","LU1066051811.HKD","LU0238689110.USD","LU1023059063.AUD","LU0130102774.USD","LU0098860793.USD","MDTX","BK4550","JDOC","BK4568","LU0265550946.USD","LU1066051498.USD","IE00BJT1NW94.SGD","LU0965508806.USD","LU2089984988.USD","BK4548","MRNA","BK4501","LU0203347892.USD","LU0265550359.USD","MRNX","IE00BN8TJ469.HKD","LU0477156953.USD","LU1430594728.SGD","LU0211331839.USD","IE00BSNM7G36.USD","LU0823416689.USD","LU1116320901.HKD","RXL","GDOC","GNOM","LU2461242641.AUD","LU0208291251.USD","BMED","LU0432979614.USD","LU1934455277.USD","LU2491050154.USD","LU0689626769.HKD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU2112291526.USD","VHT","LU0203345920.USD","IE00B4R5TH58.HKD","BK4139","LU1585245621.USD","IHE","LU2433249047.HKD","LU0320765489.SGD","MRNY","IYH","SG9999014559.SGD","LU1983299246.USD","BK4581","BK4007","LU1989771016.USD","LU2125909247.SGD","LU0648001328.SGD","LU1291159041.SGD","SG9999001176.SGD","LGHT","IE00BJJMRZ35.SGD","WDNA","LU0942090050.USD","LU1934455194.USD","LU1989772840.SGD","LU2357627491.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","PPH","LU0868494617.USD","161726","LU1917777945.USD","LU0965509101.SGD","LU1989772923.USD","LU0106261372.USD","FHLC","LU1037948897.HKD","LU2106854487.HKD","LU1201861249.SGD","LU2324357040.USD","HRTS","IE00B2B36J28.USD","SG9999001176.USD","LU2468319806.SGD","LU2125154935.USD","LU1941712264.USD","LU0006306889.USD","LU0980610538.SGD","PAWZ","BNTX","TRUH","LU2491049909.HKD","LU2360032135.SGD","LU1116320737.USD","BK4551","LU1093756168.USD","PSYK","LU0124676726.USD","MRK","FTXH","LU1934455863.HKD","LU1035773651.USD","BK4532","LU2023250504.SGD","IDNA","LU2361044949.HKD","SG9999002232.USD","IE00B1BXHZ80.USD","LU1699723380.USD","LU0130517989.USD","LU0861579265.USD","LU1929549753.HKD","LU0965509283.SGD","IBBQ","LU0234572021.USD","BK4534","LU0122379950.USD","LU0289739699.SGD","LU0266013472.USD","BK4559","LU2125909593.SGD","LU1061106388.HKD","IE00BLSP4239.USD","LU2023250843.SGD","XLV","LU0320765646.SGD","SG9999015358.SGD","SG9999013999.USD","LU1162221912.USD","LU2491050071.SGD","LU1093756325.SGD","LU2361044865.SGD","XBI","SG9999001440.SGD","SG9999014575.USD","LU0070302665.USD","LU0058720904.USD","LU1571399168.USD","LU0985320562.USD","LU2361045086.USD","LU1057294990.SGD","LU1923622614.USD","BK4533","IE0002141913.USD","LU0965509010.AUD","IE0009355771.USD","LU2125154778.USD","BK4585","LU1037948541.HKD","SG9999002224.SGD","LU1066051225.USD","SG9999014567.USD","LU1974910355.USD","BK4588","LU0868494708.USD","BK4516","LU0859254822.USD","SG9999015341.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662095611","title":"BioNTech美股盤前跌約10%，公司宣佈終止二期結直腸癌臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662095611","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662095611?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 21:17","pubTimestamp":1787923026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662638095","title":"BIONTECH結束二期結直腸癌臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662638095","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662638095?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 21:14","pubTimestamp":1787922887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060177","title":"台裕製藥提交針對HER2陽性乳腺癌的抗體藥物偶聯物生物類似藥TSY-110的臨床試驗申請。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060177","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 20:03","pubTimestamp":1787918605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","BMED","LU1992135399.USD","PPH","BK4585","LU2272731782.SGD","MDTX","XPH","IBB","LU2272731865.HKD","LU1992135472.HKD","IBBJ","IBBQ","LU2473716301.USD","LU2322448957.HKD","IE00B5TLWC47.USD","LU2322448791.USD","PSYK","LU2272731600.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069588","title":"焦點-歷經一個世紀的失敗後終於取得成功：揭秘莫德納和默克癌症疫苗的突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069588","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662069588?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 18:01","pubTimestamp":1787911290,"startTime":"0","endTime":"0","summary":"焦点-历经一个世纪的失败后终于取得成功：揭秘莫德纳和默克癌症疫苗的突破Michael Erman/Julie Steenhuysen路透8月28日-8月13日晚，莫德纳公司MRNA.O首席执行官斯特凡·班塞尔正在一家黎巴嫩餐厅为朋友庆祝生日，这时他接到了电话。此前，一些试图训练免疫系统针对一两个特定肿瘤突变的癌症疫苗均以失败告终。美国可能最早于明年批准该疫苗。莫德纳股价此前较新冠疫情期间的高点已下跌约90%，但自疫苗试验结果公布以来已上涨逾130%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4T44P0PR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JDOC","WDNA","BK4007","LU1093756168.USD","IE00B1BXHZ80.USD","LU2461242641.AUD","SG9999001176.USD","IHE","LU0477156953.USD","SG9999002224.SGD","LU0265550946.USD","LU0266013472.USD","SG9999001440.SGD","IXJ","SG9999014575.USD","LU0980610538.SGD","LU1066053197.SGD","BK4548","LU2125909247.SGD","LU1585245621.USD","LU0238689110.USD","LU0823416689.USD","BK4559","IE00B2B36J28.USD","LU1116320737.USD","LU0203347892.USD","LU0211331839.USD","IE00BLSP4452.SGD","LU0985320562.USD","LU2125154935.USD","LGHT","LU2491050071.SGD","LU1066051811.HKD","LU0289739699.SGD","LU1066051498.USD","LU2433249047.HKD","LU1941712348.USD","BK4585","BMED","IE00BJJMRZ35.SGD","PAWZ","VHT","LU0689626769.HKD","IE00BLSP4239.USD","LU1430594728.SGD","IE0002141913.USD","LU1934455194.USD","BK4532","LU1201861249.SGD","IE000M9KFDE8.USD","MRNY","LU0203345920.USD","FHLC","MRNA","LU1699723380.USD","LU1035773651.USD","LU0070302665.USD","LU0124676726.USD","FTXH","LU1989771016.USD","LU0432979614.USD","BK4588","BK4568","LU1983299246.USD","SG9999015341.SGD","IDNA","BK4551","IYH","LU1989772840.SGD","LU2125909593.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU0868494708.USD","LU0006306889.USD","IE00BN8TJ469.HKD","LU1037948897.HKD","LU1116320901.HKD","LU2023250843.SGD","RXL","MRK","LU0942090050.USD","LU2361044949.HKD","LU1061106388.HKD","BK4501","LU2361045086.USD","IE0009355771.USD","LU0320765489.SGD","LU1057294990.SGD","LU0648001328.SGD","LU0965509010.AUD","LU2360032135.SGD","LU0965509101.SGD","LU0130517989.USD","LU1066051225.USD","GNOM","LU2468319806.SGD","LU1929549753.HKD","LU1037948541.HKD","LU0098860793.USD","LU1291159041.SGD","LU0861579265.USD","LU1974910355.USD","LU0130102774.USD","LU0868494617.USD","LU1941712264.USD","LU0265550359.USD","LU0058720904.USD","LU0320765646.SGD","IE00BJT1NW94.SGD","LU1989772923.USD","LU1923622614.USD","GDOC","LU2357627491.SGD","LU2361044865.SGD","LU1093756325.SGD","BK4534","LU2324357040.USD","LU1069347547.HKD","HRTS","SG9999014559.SGD","LU0965509283.SGD","IE00BFTCPJ56.SGD","SG9999001176.SGD","LU2106854487.HKD","SG9999014542.SGD","LU0208291251.USD","LU2112291526.USD","BK4550","LU0234572021.USD","LU1934455863.HKD","LU1023059063.AUD","BK4516","LU2023250504.SGD","SG9999002232.USD","LU0859254822.USD","LU1917777945.USD","PPH","BK4139","TRUH","LU2125154778.USD","XLV","LU2491050154.USD","LU0122379950.USD","MRNX","LU2491049909.HKD","LU2089984988.USD","LU1571399168.USD","BK4533","SG9999014567.USD","LU1162221912.USD","IE00B4R5TH58.HKD","IE00BSNM7G36.USD","IE00BBT3K403.USD","LU0965508806.USD","LU0106261372.USD","SG9999015358.SGD","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}